Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
Home/Rare Diseases/CDKL5 Deficiency Disorder

Neurological & Neuromuscular

CDKL5 Deficiency Disorder (CDD) Clinical Trials

Also called CDD, CDKL5-related infantile spasms, CDKL5-associated developmental and epileptic encephalopathy

CDKL5 deficiency disorder is a rare developmental and epileptic encephalopathy caused by mutations in the CDKL5 gene located on the X chromosome. The condition typically presents in the first weeks to months of life with frequent, treatment-resistant seizures that persist throughout life. Beyond seizures, individuals experience severe limitations in motor function, cognitive development, and vision.

In plain words, CDKL5 deficiency disorder is a genetic condition that causes seizures starting in the first months of life. Most people have several seizures a day that are hard to control, along with major delays in development and movement.

Get an email when new CDKL5 Deficiency Disorder trials open or the FDA decides. Get alerts

CDKL5 Deficiency Disorder

Where treatments stand, from ClinicalTrials.gov and FDA labels

Also 2 studies with no phase, like observational studies.

FDA review0

No decision pending. FDA calendar

FDA-approved medicines1

Ztalmy

CDKL5 Deficiency Disorder has 1 FDA-approved medicine, 3 open or active clinical trials (1 recruiting), and no pending FDA decision.

Labels checked October 21, 2026. Corticosteroids and immune globulins count once each.Download the data

Latest for CDKL5 Deficiency Disorder

See all trialsThe week in rare disease

Each date is the day a change was posted. Open an item to see where things stand now.

More about CDKL5 Deficiency Disorder

The hallmark feature is extremely early seizure onset combined with profound developmental impairment. Most people with CDKL5 continue to have multiple seizures daily despite anti-seizure medications. Additional challenges include movement disorders, sleep problems, and feeding difficulties that significantly impact quality of life for individuals and families.

Keep reading about CDKL5 Deficiency Disorder

Diagnosis requires genetic testing to identify CDKL5 mutations. While there is no cure, treatment focuses on seizure management, physical and occupational therapy, and supportive care to maximize quality of life. Ztalmy (ganaxolone), approved in March 2022, is the only medicine the FDA has approved for seizures in CDKL5 deficiency disorder, for people 2 years and older.

What are the symptoms of CDKL5 Deficiency Disorder?

These are common symptoms of CDKL5 Deficiency Disorder, and how strong they are varies from person to person.

  • Severe seizures starting in infancy (usually by 3 months of age)
  • Profound developmental delays affecting movement, speech, and cognition
  • Vision problems including reduced eye focus and abnormal eye movements
  • Sleep disruption with inability to sleep through the night
  • Involuntary movements such as hand and leg jerking or dystonia
  • Feeding difficulties and gastrointestinal problems like reflux and constipation

Who gets CDKL5 Deficiency Disorder?

CDKL5 is an X-linked condition affecting both males and females, though females are diagnosed about 4 times more often. Seizures begin within the first year of life, typically by 3 months. Males who inherit the condition often experience more severe developmental delays. About 99% of cases arise from new genetic mutations rather than being inherited from parents.

Next steps: find trials you might fitsee approved treatmentsget help payingget alerts

Which medicines are FDA-approved for CDKL5 Deficiency Disorder?

There is currently 1 FDA-approved medication for CDKL5 Deficiency Disorder.

ganaxolone
Immedica Pharma
Search

Source: openFDA drug labeling data. This list may not include all treatments. Always consult your doctor.

How to get help paying for CDKL5 Deficiency Disorder treatment

Charity funds and drugmaker programs for CDKL5 Deficiency Disorder, checked at the source.

Which insurance do you have? Pick one to see what fits. Tap it again to clear.
Your insurance
Drugmaker programs
Open a medicine for who qualifies, by insurance type.

Open the full patient assistance finder →

Side effects people have reported to the FDA

Side effects people have reported to the FDA

Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.

Loading side effect data...

Diagnosis and genetic testing

Genetic testing for CDKL5 Deficiency Disorder

Genetic testing can confirm a diagnosis, guide treatment decisions, and identify family members who may be at risk.

The CDKL5 gene page lists every condition Orphanet links to the gene and the open trials that name it.

Finding labs...

Trusted CDKL5 Deficiency Disorder resources

Reputable organizations and medical references for learning more about CDKL5 Deficiency Disorder, including disease registries, foundation resources, and clinical guidelines.

Active clinical trials for CDKL5 Deficiency Disorder

Use this CDKL5 Deficiency Disorder clinical trial finder to see the 1 study recruiting patients and 2 not yet recruiting in the United States and worldwide, with eligibility criteria in plain English. Of these, 2 test a treatment and 1 is an observational study or registry; each card says which. Every trial comes from ClinicalTrials.gov.

Jump to the trial list, the site map or the pipeline timeline.

Note: Trial recruitment statuses on ClinicalTrials.gov may not immediately reflect recent FDA decisions, sponsor announcements, or enrollment changes. Always confirm a trial's current status directly with the study coordinator before making plans.

3 active trials worldwide
Filter:
Sort:
Not yet recruitingTreatment trialPhase 3Recently updatedNCT05249556

Open-label, Single-arm Trial of Ganaxolone in CDD Patients 6 Months to Less Than 2 Years Old

Intervention: Ganaxolone

Sponsor: Immedica Pharma AB

The goal of this clinical trial is to learn how patients with CDKL-5 deficiency disorder (CDD) aged 6 months to 2 years of age respond to treatment with ganaxolone. The main questions the trial aims to answer are:

Ages 6 Months to 2 Years
Expected to start Mar 2027Updated 2 weeks agoEst. Dec 2029 (~3y 1m)
Not yet recruitingTreatment trialNo updates in a whileNCT07602205

Efficacy and Safety of Daily Home-based Hyperthermic Baths for Reducing Epileptic Seizures in CDKL5 Deficiency Disorder: A PROBE Clinical Trial

Intervention: Home-based hyperthermic Baths

Sponsor: Xuanwu Hospital, Beijing

The primary objective of this research is to study the efficacy and safety of daily, home-based hyperthermic baths for reducing epileptic seizures in CDKL5 Deficiency Disorder.

Ages 6 Months to 14 Years
Expected to start Aug 2026Updated 6 months agoEst. Dec 2027 (~1y 1m)
RecruitingObservational study, no treatment givenHasn't posted an update in over a yearNCT05558371

International CDKL5 Clinical Research Network

Intervention: No intervention.

Sponsor: University of Colorado, Denver

Pathogenic variants in the Cyclin-dependent kinase like 5 (CDKL5) gene cause CDKL5 deficiency disorder (CDD, MIM 300672, 105830), a severe developmental and epileptic encephalopathy associated with cognitive and motor impairments and cortical visual impairment. While capability f...

Ages 1 Month to 100 Years
Started Feb 2021Updated 2 years agoEst. Feb 2026
Find CDKL5 Deficiency Disorder trials near you, ranked by distance →
Active trial locations8 cities in the US
A study site. Select it to see its trials and get directions. Several sites close together. Select the number to zoom in.

Trial Pipeline

Feb 2021 to Dec 2029
2022
2024
2026
2028
now
Phase 3
Observational
Observational
RecruitingNot yet recruitingDelayed startTodayHover a bar for trial details

Read more about CDKL5 Deficiency Disorder trials

Need help understanding these trials?
Answers with sources, in plain English
Start withor ask
Run a CDKL5 Deficiency Disorder foundation or patient group?
You can put this live trial list on your own website. It updates itself, and it's free.
Get the embed code →

Data from ClinicalTrials.gov, U.S. National Library of Medicine.
Always talk to your doctor before considering a clinical trial.

CDKL5 Deficiency Disorder patient communities

Facebook groups, Reddit communities and YouTube channels where CDKL5 Deficiency Disorder patients, caregivers and advocacy groups talk.

Companies developing CDKL5 Deficiency Disorder treatments

Drugmakers that list CDKL5 Deficiency Disorder in their rare disease portfolio, 2 in all.

Questions people ask about CDKL5 Deficiency Disorder